GENinCode PLC on Tuesday said the UK National Health Service has set aside a budget to expand use of the company’s polygenic testing for heart disease.
Shares in GENinCode were up 10% to 16.00 pence each in London on Tuesday midday.
The Manchester-based biotechnology company said the NHS budget will accelerate use of GENinCode’s Lipid inCode testing for the diagnosis and treatment of inherited hypercholesterolemia to prevent cardiovascular disease.
GENinCode said Lipid inCode is the first commercial polygenic test to prevent cardiovascular disease to be implemented by the NHS, and the expanded use supports the NHS’s 10-year plan to identify at least 25% of people suffering with familial hypercholesterolemia by 2024.
The company added the expansion is part of a collaboration with the Academic Health Science Network for the North East and North Cumbria in England to use Lipid inCode testing in primary care.
GENinCode Chief Executive Officer Matthew Walls said: ‘We look forward to supporting the NHS in reaching its long term goal to diagnose patients with hypercholesterolemia and provide earlier risk assessment of cardiovascular disease to improve health outcomes.’
Copyright 2023 Alliance News Ltd. All Rights Reserved.
